PMID- 11231442
OWN - NLM
STAT- MEDLINE
DCOM- 20010419
LR  - 20061115
IS  - 0002-8703 (Print)
IS  - 0002-8703 (Linking)
VI  - 141
IP  - 3
DP  - 2001 Mar
TI  - Elevated interleukin-6 levels in patients with asymptomatic left ventricular 
      systolic dysfunction.
PG  - 435-8
AB  - BACKGROUND: Elevated interleukin-6 (IL-6) levels are present in patients with New 
      York Heart Association (NYHA) class III and IV congestive heart failure (CHF) and 
      are associated with a poor prognosis. We sought to determine whether elevated 
      IL-6 levels are also present in patients with left ventricular (LV) dysfunction 
      but without clinical symptoms. METHODS: Blood samples were obtained from the 
      femoral artery of 58 patients who underwent cardiac catheterization for 
      recognized clinical indications. In a subgroup of 44 patients, samples were also 
      obtained from the femoral vein, the left main coronary artery, and the coronary 
      sinus. Patients with prior coronary artery bypass surgery, recent acute coronary 
      syndrome, or steroid therapy were excluded. All samples were obtained before 
      heparin or contrast administration. IL-6 was measured by enzyme-linked 
      immunosorbent assay and values are expressed in picograms per milliliter. 
      RESULTS: Three groups of patients were identified: controls, no CHF, LV ejection 
      fraction >/=0.55 (n = 32); asymptomatic LV systolic dysfunction, no CHF, LV 
      ejection fraction <0.55 (n = 14); and CHF, pulmonary edema (n = 12). IL-6 levels 
      were higher at all sampling sites in both the asymptomatic LV systolic 
      dysfunction and CHF groups compared with controls with the IL-6 levels inversely 
      related to LV ejection fraction. CONCLUSIONS: Elevated IL-6 levels are present in 
      patients with LV dysfunction even in the absence of the clinical syndrome of CHF. 
      These data suggest that IL-6 may be involved in the progression of subclinical LV 
      dysfunction to clinical CHF. IL-6 may be a marker of patients at risk for 
      progression to clinical CHF or a novel target for therapeutic intervention.
FAU - Raymond, R J
AU  - Raymond RJ
AD  - Cardiac Catheterization Laboratory, University of North Carolina Hospitals, 
      Chapel Hill, NC 27514, USA.
FAU - Dehmer, G J
AU  - Dehmer GJ
FAU - Theoharides, T C
AU  - Theoharides TC
FAU - Deliargyris, E N
AU  - Deliargyris EN
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Interleukin-6)
SB  - IM
MH  - Female
MH  - Humans
MH  - Interleukin-6/*analysis
MH  - Male
MH  - Middle Aged
MH  - Systole/physiology
MH  - Ventricular Dysfunction, Left/*blood/physiopathology
EDAT- 2001/03/07 10:00
MHDA- 2001/04/21 10:01
CRDT- 2001/03/07 10:00
PHST- 2001/03/07 10:00 [pubmed]
PHST- 2001/04/21 10:01 [medline]
PHST- 2001/03/07 10:00 [entrez]
AID - S0002-8703(01)95658-3 [pii]
AID - 10.1067/mhj.2001.113078 [doi]
PST - ppublish
SO  - Am Heart J. 2001 Mar;141(3):435-8. doi: 10.1067/mhj.2001.113078.